Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Opportunities to Optimize Cancer Policies Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Opening Session Panel Discussion

Advertisement

Advertisement




Apr
22
Today In Oncology
Bispecific Antibody Shows Deep Remission in Patients With Relapsed/Refractory Follicular Lymphoma
Adebrelimab and Bevacizumab Plus Platinum Chemotherapy in Triple-Negative Breast Cancer With Brain Metastases
Pretreatment MRI Prognostic Information After Radical Prostatectomy
Early-Onset ICI-Related Myocarditis Linked to Increased Mortality
First-Line Zongertinib in Advanced HER2-Mutant NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo